cell engineering and complex cytokines.
Brooklyn ImmunoTherapeutics (BTX) is a clinical-stage biopharmaceutical company committed to creating a world where patients and families with high unmet medical needs have access to effective treatments.
We are pioneers in using the latest technologies such as synthetic mRNA, cellular reprogramming, gene editing, and complex human-derived mixed cytokines. These advances fuel our ongoing programs, including iPSC-derived MSC (iMSC), gene-edited iMSC, and in vivo gene editing. Additionally, we have developed the IRX-2 immuno-therapy, which is approaching the conclusion of its Phase2B study.